Pharmacokinetics (PK), Pharmacodynamics (PD) and Integrated PK/PD Modeling of a Novel Long Acting FGF21 Clinical Candidate PF-05231023 in Diet-Induced Obese and Leptin-Deficient Obese Mice
| Autor: | Yimin Zhu, Barbara Bernardo, Alison Logan, Chandra Vage, Saswata Talukdar, Jeffrey R. Chabot, Roberto A. Calle, Yan Weng, Qingyun Yan, Martin B. Brenner |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2015 |
| Předmět: |
Blood Glucose
Leptin Male medicine.medical_specialty FGF21 Time Factors Injections Subcutaneous lcsh:Medicine Mice Obese Pharmacology Biology Antibodies Monoclonal Humanized Models Biological Pharmacokinetics In vivo Internal medicine Weight Loss medicine Animals Obesity lcsh:Science PK/PD models Glucose tolerance test Multidisciplinary medicine.diagnostic_test lcsh:R Glucose Tolerance Test Bioavailability Diet Fibroblast Growth Factors Endocrinology Pharmacodynamics lcsh:Q Administration Intravenous Diet-induced obese Research Article |
| Zdroj: | PLoS ONE PLoS ONE, Vol 10, Iss 3, p e0119104 (2015) |
| ISSN: | 1932-6203 |
| Popis: | Pharmacological administration of fibroblast growth factor 21 (FGF21) improves metabolic profile in preclinical species and humans. FGF21 exerts its metabolic effects through formation of beta-klotho (KLB)/FGF receptor 1c FGFR1c complex and subsequent signaling. Data from various in vitro systems demonstrate the intact C- and N-terminus of FGF21 is required for binding with KLB, and interaction with FGFR1c, respectively. However the relative roles of the termini for in vivo pharmacological effects are unclear. Here we report PF-05231023, a long-acting FGF21 analogue which is unique in that the half-life and subcutaneous (s.c.) bioavailability of the intact C-terminus are significantly different from those of the intact N-terminus (2 vs. 22 hr for half-life and 4~7 vs. ~50% SC bioavailability). Therefore, this molecule serves as a valuable tool to evaluate the relative roles of intact C-terminus vs. N-terminus in in vivo pharmacology studies in preclinical species. We determined the effects of PF-05231023 administration on body weight (BW) loss and glucose reduction during an oral glucose tolerance test (OGTT) following SC and intravenous (i.v.) administration in diet-induced obese (DIO) and leptin-deficient obese (ob/ob) mice, respectively. Our data show that the intact N-terminus of FGF21 in PF-05231023 appears to be sufficient to drive glucose lowering during OGTT and sustain BW loss in DIOs. Further, PK/PD modeling suggests that while the intact FGF21 C-terminus is not strictly required for glucose lowering during OGTT in ob/ob mice or for BW reduction in DIO mice, the higher potency conferred by intact C-terminus contributes to a rapid initiation of pharmacodynamic effects immediately following dosing. These results provide additional insight into the strategy of developing stabilized versions of FGF21 analogs to harness the full spectrum of its metabolic benefits. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|